Photo taken from Earle Burgess/LinkedIn
Nov 6, 2023, 00:56
Earle Burgess: We finally have evidence that a triplicate regimen in bladder cancer is better than chemo alone
Earle Burgess, Chief, Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, made the following post on LinkedIn:
“Gemcitabine (Gem) + Cisplatin (Cis) + Nivolumab (Nivo) is better than Gem + Cis alone in advanced urothelial cancer.
We finally have evidence that a triplicate regimen in bladder cancer is better than chemo alone: the CheckMate 901 study.
Never mind that chemo + pembrolizumab or + atezolizumab, both immune checkpoint inhibitors (ICI) similar to nivolumab, were really no better than chemo alone.
What’s special about Nivo that we finally got a positive chemo + ICI trial?
Let’s take a look at the CM901 trial to find out….”
Source: Earle Burgess/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 15:26
Dec 23, 2024, 15:13
Dec 23, 2024, 15:10
Dec 23, 2024, 14:55
Dec 23, 2024, 14:52